The Colorado, US-based firm – which aims to discover new uses for previously approved drugs – acquired rights to the technology this week and now plans to accelerate its filing plan for its product, Zertane.
CEO Don Wingerter said: “The Zertane commercialization plan is on course as outlined in the previous press releases and securities filings.
“We are committed to complete the development of a combination product of Zertane with a PDE5 inhibitor to simultaneously treat both premature ejaculation and erectile dysfunction.”